Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bradford Lawrence

Physician Assistant Hickory, NC Physician Assistant

NPI 1376505651 CMS profile 10890792

5045 Hickory Blvd, Hickory, NC 28601

Open in the dashboard

General payments

$18,058

1,261 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bradford Lawrence of Hickory, NC is reported in the CMS Open Payments database as having received $18,058 across 1,261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,136 261
2024 General $3,267 209
2023 General $3,587 266
2022 General $3,488 248
2021 General $3,579 277

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradford Lawrence
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Bradford Lawrence were reported at $4,136. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Bradford Lawrence Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,579 $132 $37–$438 $132
2022 $3,488 $155 $48–$522 $149
2023 $3,587 $167 $52–$557 $160
2024 $3,267 $178 $55–$600 $164
2025 $4,136 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,552 247 payments
  2. AbbVie, Inc. $2,036 170 payments
  3. AstraZeneca Pharmaceuticals LP $2,030 102 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $1,204 56 payments
  5. Kowa Pharmaceuticals America, Inc. $1,113 97 payments
  6. Pfizer Inc. $811 64 payments
  7. Lilly USA, LLC $797 55 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $654 50 payments
  9. Amgen Inc. $570 36 payments
  10. Otsuka America Pharmaceutical, Inc. $551 35 payments
  11. Other $5,740 349 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,858 1,258 payments
  2. Education $200 3 payments
Products named General payments · program years 2021–2025
  1. BREZTRI $1,495 75 payments
  2. Ozempic $1,332 132 payments
  3. Kerendia $1,204 56 payments
  4. RYBELSUS $1,164 123 payments
  5. Livalo $833 80 payments
  6. UBRELVY $799 62 payments
  7. FARXIGA $638 28 payments
  8. Wegovy $567 60 payments
  9. NURTEC ODT $557 47 payments
  10. REXULTI $551 35 payments
  11. Other $14,299 985 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 173 drugs

Part D claims

11,360

Median for Physician Assistant: 241

Drug cost

$857,731

Median for Physician Assistant: $4,110

Branded share of claims

22.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 157 $155,793
Trulicity Dulaglutide Brand 59 $73,259
Eliquis Apixaban Brand 104 $64,572
Farxiga Dapagliflozin Propanediol Brand 48 $49,451
Januvia Sitagliptin Phosphate Brand 58 $41,590
Jardiance Empagliflozin Brand 30 $28,963
Mounjaro Tirzepatide Brand 24 $26,966
Repatha Sureclick Evolocumab Brand 36 $25,787
Xarelto Rivaroxaban Brand 22 $25,051
Kerendia Finerenone Brand 39 $24,676

The 10 drugs with the highest cost, of 173 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$57,075

Of which drugs: $12,377

Medicare patients

142

Average age 73

Services billed

1,415

71 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 35%
Ischemic heart disease 32%
Depression 30%
Chronic kidney disease 19%
Heart failure 13%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 34 34 $9,866
Vaccine for influenza for injection into muscle 90662 Office 28 28 $2,291
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 33 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 45 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
$337 39 —
BREZTRI
$306 18 —
REXULTI
$189 — —
Veozah
$157 — —
FARXIGA
$148 48 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 45 with Patron

Records

1,261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record